Total Return:60.79%(TTM)
Over the latest trailing 12-month period, total return cagr is +60.79%. The comparable SPY value is +20.46%. Year-to-date total return is +27.73%. Total return includes price appreciation and reinvested dividends.
Growth of $10,000 in WST
$784,372
(78.4x return)
Invested on Jun 27, 1996
Growth of $10,000 in SPY (S&P 500)
$182,810
(18.3x return)
Invested on Jun 27, 1996
Hypothetical Growth of $10,000
This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.
Recent Performance Indicators
YTD Total Return
+27.7%
1-Year Total Return
+60.7%
Current Dividend Yield
0.25%
Price CAGR vs. Total Return CAGR
Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.
| Holding Period | Price CAGR | Total Return CAGR | Dividend Addition |
|---|---|---|---|
| 1 Year | +60.3% | +60.8% | +0.5% |
| 3 Years | (1.3%) | (1.0%) | +0.3% |
| 5 Years | (0.5%) | (0.3%) | +0.3% |
| 10 Years | +17.0% | +17.4% | +0.4% |
| 15 Years | +20.5% | +21.3% | +0.8% |
| 20 Years | +16.2% | +17.2% | +1.0% |
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green